Purdue Pharma LP clinical trials

Acquired by Knoa Pharma, May 1, 2026 · source ↗

The registry lists 58 studies whose lead sponsor is Purdue Pharma LP. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 3, 2025.

Studies

Recruiting first, then most recently updated. Showing 50 of 58. List all 58 → · All Knoa Pharma studies →

• Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mgCompletedNCT06719986Phase 1

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health SystemCompletedNCT03299556

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in ChildrenTerminatedNCT04987762Phase 4

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)TerminatedNCT04507204Phase 4

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Clinical Outcomes From NalmefeneWithdrawnNCT05808881Phase 4

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring OpioidsCompletedNCT01192295Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back PainCompletedNCT01452529Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.CompletedNCT01400139Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the KneeCompletedNCT03028870Phase 2

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy VolunteersCompletedNCT01999114Phase 1

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• A Study to Evaluate the Analgesic Efficacy and Safety of VM902A in Subjects With Osteoarthritis (OA) of the KneeTerminatedNCT02847702Phase 2

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in ChildrenCompletedNCT01324570Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Safety, Pharmacokinetics (PK), and Effectiveness of Hydrocodone Bitartrate (HYD) Extended-Release Tablets in ChildrenWithdrawnNCT02542098Phase 2

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Experimental Biomarker Study for Pain ThresholdsCompletedNCT02695745Phase 1

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe PainWithdrawnNCT01324544Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different FacilitiesCompletedNCT01101321Phase 1

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative PainCompletedNCT00465647Phase 4

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back PainCompletedNCT01358526Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001CompletedNCT01369615Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back PainCompletedNCT01427283Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back PainCompletedNCT01427270Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult SubjectsCompletedNCT02243241Phase 1

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and KetoconazoleCompletedNCT01259115Phase 1

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)CompletedNCT01688947Phase 2

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the KneeCompletedNCT01688934Phase 2

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• An Analgesic Study to of V117957 for the Treatment of Postsurgical Pain Due to Third Molar ExtractionTerminatedNCT01900795Phase 2

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Low Back Pain.CompletedNCT00315874Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Pharmacokinetics and Safety of ORF Tablets in Pediatric PatientsCompletedNCT01160614Phase 1

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of KneeCompletedNCT00531427Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant PainCompletedNCT00312195Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension PhaseTerminatedNCT01135524Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back PainCompletedNCT00490919Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis PainTerminatedNCT00312221Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension StudyCompletedNCT01151098Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase.TerminatedNCT00320801Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.TerminatedNCT00315458Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or KneeCompletedNCT00313846Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA PainCompletedNCT00312572Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015TerminatedNCT01125917Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee ReplacementTerminatedNCT00403234Phase 2

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest PeriodsCompletedNCT01259102Phase 1

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back PainTerminatedNCT00313014Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy VolunteersCompletedNCT01148537Phase 1

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension PhaseCompletedNCT01141283Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.CompletedNCT00315445Phase 3

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• To Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) TabletsCompletedNCT01101178Phase 1

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) TabletsCompletedNCT01101191Phase 1

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different FacilitiesCompletedNCT01101308Phase 1

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) TabletsCompletedNCT01100086Phase 1

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma

• To Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) TabletsCompletedNCT01101165Phase 1

  Sponsor listed in the registry: Purdue Pharma LP · First submitted before Purdue Pharma LP became part of Knoa Pharma